Here, we propose this combination through the controlled delivery of both monotherapies: paclitaxel drug + survivin gene therapy, encapsulated in proprietary polymeric nanoparticles to achieve a synergistic effect killing cancer cells. This evidence concerns the gene BIRC5 and cancer.